Harvard Clinical Research Institute (HCRI) Will Tweet Its Experts’ Commentary From “TCT 2011”

To follow/participate go to #tct2011 from your account at www.twitter.com

BOSTON--(BUSINESS WIRE)-- Experts from Harvard Clinical Research Institute (HCRI), a leading international provider of clinical trial services, will be in attendance at TCT (Transcatheter Cardiovascular Therapeutics) 2011 (Booth # 1434) and will tweet commentary and insights from the event in San Francisco, Nov. 8-10.

“We look forward to participating at TCT 2011 and to sharing the insights of HCRI faculty with the international cardiology community,” said Mordecai Kramer, Executive Director, Business Development, HCRI.

About Harvard Clinical Research Institute (HCRI)

HCRI (www.hcri.harvard.edu) is a not-for-profit organization that advances the research of pharmaceuticals, biologics, and medical devices by developing collaborations between industry and academia.



CONTACT:

Ronald Trahan Associates Inc.
Ronald Trahan, +1 508-816-6730
President
[email protected]
or
HCRI
Devan Rousseau, +1-617-307-5527
Business Development Associate
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Medical Devices  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.